Company: AIBT
Filing Date: 2025-07-03
Form Type: 253G2
Source: 0001096906-25-001087
Chunk: 66

Company: AIBOTICS, INC.
Filing Date: 2025-07-03
Form: 253G2
Chunk 66
---
000,000 |
| 250,000        |     | $                               |  40,000,000 |
| 250,000        |     | $                               |  60,000,000 |
| 250,000        |     | $                               |  80,000,000 |
| 250,000        |     | $                               | 100,000,000 |

Stock Grants – Significant Transactions Upon the Company closing a Significant Transaction, the CEO shall be granted shares of AIBiotics common stock or a new series of AIBiotics preferred shares that is convertible into AIBiotics common stock equal to 5% of the value of all the consideration, including any stock, cash or debt of such completed transaction. A “Significant Transaction” shall mean a financing of at least $500,000 or the closing of an acquisition with a valuation of at least $1,000,000 for AIBiotics. As of March 31, 2025 and December 31, 2024, the Company had not granted any shares in relation to a Significant Transaction. As of March 31, 2025 and December 31, 2024, there are no amounts accrued related to the bonuses. Board Compensation As of March 31, 2025 and December 31, 2024, the Company had accrued expenses from board compensation of $150,000 and $160,000, respectively. Accrued board compensation is included as part of Accounts payable and accrued expenses on the consolidated balance sheets. NOTE 6 – PROMISSORY AND CONVERTIBLE NOTES On August 27, 2021, the Company issued a lender (“Lender A”) a convertible note payable with principal of $500,000 and an original issue discount of $50,000. The note matures after 24 months and has an effective interest rate of 8%. As of March 31, 2025 and December 31, 2024, this convertible note payable was in default and therefore classified as a current liability. Default interest accrues at a rate of 20% upon default, and the default conversion price is $0.75 per share. As of March 31, 2025 and December 31, 2024, the Company had an outstanding principal amount of $500,000 due to this lender as a result of the note. As of December 31, 2024, the Company converted $110,000 of accrued interest into common shares pursuant to the terms of